ELI LILLY & Co — Director's Dealing 2023

Feb 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2023-02-10

Reporting Person: White Anne E. (EVP & Pres, Lilly Neuroscience)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-10	Common Stock	A	8562	$345.12	Acquired	62926	Direct
2023-02-10	Common Stock	S	2500	$342.76	Disposed	60426	Direct
2023-02-13	Common Stock	S	2500	$346.47	Disposed	57926	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-10	Restricted Stock Unit	$	A	4124	Acquired	2024-02-01	Common Stock (4124.0)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2022.

F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.